K Kondo

Summary

Affiliation: Mitsubishi Tanabe Pharma Corporation
Country: Japan

Publications

  1. ncbi Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study
    K Kondo
    Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
    Diabetes Obes Metab 12:246-51. 2010
  2. ncbi An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes
    H Fujii
    Tama center Mirai Clinic, Ochiai, Tama City, Tokyo, Japan
    Int J Clin Pract 64:1512-9. 2010

Collaborators

  • T Kadowaki
  • H Fujii
  • A Ohno
  • H Nishimura
  • T Miyakawa
  • A Ueki
  • D Matsuda
  • M Kato
  • M Takesue
  • H Takamura
  • Y Watanabe

Detail Information

Publications2

  1. ncbi Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study
    K Kondo
    Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
    Diabetes Obes Metab 12:246-51. 2010
    ..To evaluate the plasma glucose-reducing activity and safety of colestilan, a bile acid sequestrant, in patients with type 2 diabetes...
  2. ncbi An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes
    H Fujii
    Tama center Mirai Clinic, Ochiai, Tama City, Tokyo, Japan
    Int J Clin Pract 64:1512-9. 2010
    ..The aim of study was to evaluate the safety and efficacy of insulin detemir as a basal insulin switching from neutral protamine Hagedorn insulin (NPH) and insulin glargine in patients with diabetes on an intensive insulin therapy regimen...